Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225684 | 0.86 | RAB9A (0.63) | CYP1B1MAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL31398692 | 0.86 | RAB9A (0.63) | CYP1B1MAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL7660164 | 0.86 | RAB9A (0.63) | CYP1B1MAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL351853 | 0.86 | RAB9A (0.63) | CYP1B1MAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL10050575 | 0.83 | CYP1B1 (0.65) | CYP1A1CYP1A2CYP2D6CYP1B1MAPT | |
| SCHEMBL9567804 | 0.83 | MAPT (0.70) | CYP1A1CYP1A2CYP2D6CYP1B1MAPT | |
| SCHEMBL13203457 | 0.83 | RAB9A (0.51) | CYP1A1CYP1B1MAPTALDH1A1MAPK1 | |
| SCHEMBL29018468 | 0.82 | MAPT (0.67) | CYP1B1MAPTHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL13276183 | 0.81 | CYP1B1 (0.61) | CYP1B1MAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL17536853 | 0.81 | BCHE (0.68) | CYP1A1CYP1A2CYP2D6CYP1B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | CYP1A1 201/4885CYP1A2 276/4885CYP2D6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.